Reaction of the Anticancer Organometallic Ruthenium Compound, [(<svg style="vertical-align:-4.698pt;width:40.625px;" id="M1" height="26.7875" version="1.1" viewBox="0 0 40.625 26.7875" width="40.625" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.022,-0,0,-.022,.062,20.875)"><path id="x1D702" d="M471 401q0 -32 -14 -91l-83 -376q-30 -146 -21 -180l-7 -15q-22 0 -47.5 23.5t-25.5 40.5q0 49 53 271l53 224q4 18 6.5 31t3.5 22.5t1 15t-2 9t-4.5 4.5t-6.5 1q-31 0 -100.5 -63.5t-126.5 -145.5q-16 -53 -40 -163q-48 -11 -74 -21l-7 8l82 341q9 36 -4 36
q-8 0 -28.5 -14t-38.5 -32l-17 22q41 43 85 71t66 28q23 0 23 -39q0 -19 -10 -64l-24 -103h2q77 101 201 182q37 24 74 24q31 0 31 -47z" /></g><g transform="matrix(.016,-0,0,-.016,11.137,10.125)"><path id="x36" d="M137 343l67 33q37 17 63 17q79 0 129.5 -53t50.5 -131q0 -92 -58 -156.5t-147 -64.5t-147 68t-58 182q0 63 17 119t43 95.5t61.5 72t69 52t67.5 31.5q62 22 128 33l6 -32q-56 -11 -108 -35q-149 -71 -184 -231zM227 337q-47 0 -95 -27q-6 -23 -6 -70q0 -93 36 -155.5
t96 -62.5q53 0 78 45.5t25 105.5q0 68 -35 116t-99 48z" /></g><g transform="matrix(.022,-0,0,-.022,19.288,20.875)"><path id="x2D" d="M300 253l-14 -55h-229l14 55h229z" /></g><g transform="matrix(.022,-0,0,-.022,27.268,20.875)"><path id="x1D45D" d="M570 304q0 -108 -87 -199q-40 -42 -94.5 -74t-105.5 -43q-41 0 -65 11l-29 -141q-9 -45 -1.5 -58t45.5 -16l26 -2l-5 -29l-241 -10l4 26q51 10 67.5 24t26.5 60l113 520q-54 -20 -89 -41l-7 26q38 28 105 53l11 49q20 25 77 58l8 -7l-17 -77q39 14 102 14q82 0 119 -36
t37 -108zM482 289q0 114 -113 114q-26 0 -66 -7l-70 -327q12 -14 32 -25t39 -11q59 0 118.5 81.5t59.5 174.5z" /></g></svg>-Cymene)Ru(ATSC)Cl]<svg style="vertical-align:-4.47125pt;width:32.650002px;" id="M2" height="20.262501" version="1.1" viewBox="0 0 32.650002 20.262501" width="32.650002" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.022,-0,0,-.022,.062,14.638)"><path id="x50" d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" /></g><g transform="matrix(.022,-0,0,-.022,12.571,14.638)"><path id="x46" d="M493 503l-29 -4q-13 56 -28 80q-13 22 -35.5 29.5t-78.5 7.5h-76q-22 0 -27.5 -5t-5.5 -27v-238h103q66 0 82.5 12t25.5 62h29v-193h-29q-9 54 -25.5 67t-82.5 13h-103v-181q0 -64 15 -78.5t84 -19.5v-28h-272v28q61 5 74.5 19.5t13.5 78.5v399q0 64 -13 78t-72 19v28
h440q1 -40 10 -147z" /></g><g transform="matrix(.016,-0,0,-.016,24.425,20.012)"><use xlink:href="#x36" /></g></svg> with Human Serum Albumin

<table>The Scatchard plot for the binding of <b>1</b> to HSA.</table>

International Journal of Inorganic Chemistry

fig5

Figure 5

Figure 5: Reaction of the Anticancer Organometallic Ruthenium Compound, [(<svg style="vertical-align:-4.698pt;width:40.625px;" id="M1" height="26.7875" version="1.1" viewBox="0 0 40.625 26.7875" width="40.625" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.022,-0,0,-.022,.062,20.875)"><path id="x1D702" d="M471 401q0 -32 -14 -91l-83 -376q-30 -146 -21 -180l-7 -15q-22 0 -47.5 23.5t-25.5 40.5q0 49 53 271l53 224q4 18 6.5 31t3.5 22.5t1 15t-2 9t-4.5 4.5t-6.5 1q-31 0 -100.5 -63.5t-126.5 -145.5q-16 -53 -40 -163q-48 -11 -74 -21l-7 8l82 341q9 36 -4 36
q-8 0 -28.5 -14t-38.5 -32l-17 22q41 43 85 71t66 28q23 0 23 -39q0 -19 -10 -64l-24 -103h2q77 101 201 182q37 24 74 24q31 0 31 -47z" /></g><g transform="matrix(.016,-0,0,-.016,11.137,10.125)"><path id="x36" d="M137 343l67 33q37 17 63 17q79 0 129.5 -53t50.5 -131q0 -92 -58 -156.5t-147 -64.5t-147 68t-58 182q0 63 17 119t43 95.5t61.5 72t69 52t67.5 31.5q62 22 128 33l6 -32q-56 -11 -108 -35q-149 -71 -184 -231zM227 337q-47 0 -95 -27q-6 -23 -6 -70q0 -93 36 -155.5
t96 -62.5q53 0 78 45.5t25 105.5q0 68 -35 116t-99 48z" /></g><g transform="matrix(.022,-0,0,-.022,19.288,20.875)"><path id="x2D" d="M300 253l-14 -55h-229l14 55h229z" /></g><g transform="matrix(.022,-0,0,-.022,27.268,20.875)"><path id="x1D45D" d="M570 304q0 -108 -87 -199q-40 -42 -94.5 -74t-105.5 -43q-41 0 -65 11l-29 -141q-9 -45 -1.5 -58t45.5 -16l26 -2l-5 -29l-241 -10l4 26q51 10 67.5 24t26.5 60l113 520q-54 -20 -89 -41l-7 26q38 28 105 53l11 49q20 25 77 58l8 -7l-17 -77q39 14 102 14q82 0 119 -36
t37 -108zM482 289q0 114 -113 114q-26 0 -66 -7l-70 -327q12 -14 32 -25t39 -11q59 0 118.5 81.5t59.5 174.5z" /></g></svg>-Cymene)Ru(ATSC)Cl]<svg style="vertical-align:-4.47125pt;width:32.650002px;" id="M2" height="20.262501" version="1.1" viewBox="0 0 32.650002 20.262501" width="32.650002" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"><g transform="matrix(.022,-0,0,-.022,.062,14.638)"><path id="x50" d="M46 650h247q112 0 169 -41q64 -49 64 -141q0 -91 -56.5 -143t-138.5 -62q-23 -3 -45 -1l-74 19v-157q0 -63 15.5 -77t83.5 -19v-28h-271v28q60 5 74 20t14 77v400q0 65 -12.5 79t-69.5 18v28zM212 559v-245q31 -12 73 -12q59 0 102 38t43 124q0 77 -42.5 115.5
t-108.5 38.5q-44 0 -56 -12q-11 -8 -11 -47z" /></g><g transform="matrix(.022,-0,0,-.022,12.571,14.638)"><path id="x46" d="M493 503l-29 -4q-13 56 -28 80q-13 22 -35.5 29.5t-78.5 7.5h-76q-22 0 -27.5 -5t-5.5 -27v-238h103q66 0 82.5 12t25.5 62h29v-193h-29q-9 54 -25.5 67t-82.5 13h-103v-181q0 -64 15 -78.5t84 -19.5v-28h-272v28q61 5 74.5 19.5t13.5 78.5v399q0 64 -13 78t-72 19v28
h440q1 -40 10 -147z" /></g><g transform="matrix(.016,-0,0,-.016,24.425,20.012)"><use xlink:href="#x36" /></g></svg> with Human Serum Albumin 

International Journal of Inorganic Chemistry

Reaction of the Anticancer Organometallic Ruthenium Compound, [(-Cymene)Ru(ATSC)Cl] with Human Serum Albumin

Figure 5